#begin document (en_2590.txt); part 000
en_2590.txt	0	0	Biomedicine	NNP	(TOP(NP(NP*)	-	-	-	-	*	-
en_2590.txt	0	1	in	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	2	Reverse	NNP	(NP*))))	-	-	-	-	*	-

en_2590.txt	0	0	LA	NNP	(TOP(S(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	1	JOLLA	NNP	*)	-	-	-	-	*	-
en_2590.txt	0	2	,	,	*	-	-	-	-	*	-
en_2590.txt	0	3	CALIFORNIA	NNP	(NP*	-	-	-	-	*	-
en_2590.txt	0	4	–	SYM	*	-	-	-	-	*	-
en_2590.txt	0	5	Pundits	NNP	*))	-	-	-	-	*	-
en_2590.txt	0	6	have	VBP	(VP*	-	-	-	-	*	-
en_2590.txt	0	7	long	RB	(ADVP*)	-	-	-	-	*	-
en_2590.txt	0	8	predicted	VBN	(VP*	-	-	-	-	*	-
en_2590.txt	0	9	that	IN	(SBAR*	-	-	-	-	*	-
en_2590.txt	0	10	biology	NN	(S(NP*)	-	-	-	-	*	-
en_2590.txt	0	11	would	MD	(VP*	-	-	-	-	*	-
en_2590.txt	0	12	dominate	VB	(VP*	-	-	-	-	*	-
en_2590.txt	0	13	the	DT	(NP*	-	-	-	-	*	(0
en_2590.txt	0	14	twenty-first	JJ	*	-	-	-	-	*	-
en_2590.txt	0	15	century	NN	*)	-	-	-	-	*	0)
en_2590.txt	0	16	,	,	*	-	-	-	-	*	-
en_2590.txt	0	17	just	RB	(SBAR*	-	-	-	-	*	-
en_2590.txt	0	18	as	IN	*	-	-	-	-	*	-
en_2590.txt	0	19	physics	NNS	(S(NP*)	-	-	-	-	*	-
en_2590.txt	0	20	dominated	VBD	(VP*	-	-	-	-	*	-
en_2590.txt	0	21	the	DT	(NP*	-	-	-	-	*	(0
en_2590.txt	0	22	twentieth	JJ	*	-	-	-	-	*	-
en_2590.txt	0	23	century	NN	*))))))))))	-	-	-	-	*	0)
en_2590.txt	0	24	.	.	*))	-	-	-	-	*	-

en_2590.txt	0	0	But	CC	(TOP(S*	-	-	-	-	*	-
en_2590.txt	0	1	biomedical	JJ	(NP*	-	-	-	-	*	-
en_2590.txt	0	2	research	NN	*)	-	-	-	-	*	-
en_2590.txt	0	3	has	VBZ	(VP*	-	-	-	-	*	-
en_2590.txt	0	4	yet	RB	(ADVP*)	-	-	-	-	*	-
en_2590.txt	0	5	to	TO	(S(VP*	-	-	-	-	*	-
en_2590.txt	0	6	achieve	VB	(VP*	-	-	-	-	*	-
en_2590.txt	0	7	the	DT	(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	8	kind	NN	*)	-	-	-	-	*	-
en_2590.txt	0	9	of	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	10	productivity	NN	(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	11	increases	NNS	*)	-	-	-	-	*	-
en_2590.txt	0	12	that	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_2590.txt	0	13	accompanied	VBD	(S(VP*	-	-	-	-	*	-
en_2590.txt	0	14	the	DT	(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	15	industrialization	NN	*)	-	-	-	-	*	-
en_2590.txt	0	16	of	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	17	combustion	NN	(NP(NP*)	-	-	-	-	*	-
en_2590.txt	0	18	,	,	*	-	-	-	-	*	-
en_2590.txt	0	19	electricity	NN	(NP*)	-	-	-	-	*	-
en_2590.txt	0	20	,	,	*	-	-	-	-	*	-
en_2590.txt	0	21	and	CC	*	-	-	-	-	*	-
en_2590.txt	0	22	electronics	NNS	(NP*))))))))))))))	-	-	-	-	*	-
en_2590.txt	0	23	.	.	*))	-	-	-	-	*	-

en_2590.txt	0	0	Will	MD	(TOP(SQ*	-	-	-	-	*	-
en_2590.txt	0	1	the	DT	(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	2	``	``	*	-	-	-	-	*	-
en_2590.txt	0	3	century	NN	*)	-	-	-	-	*	-
en_2590.txt	0	4	of	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	5	biology	NN	(NP*)))	-	-	-	-	*	-
en_2590.txt	0	6	''	''	*	-	-	-	-	*	-
en_2590.txt	0	7	turn	VB	(VP*	-	-	-	-	*	-
en_2590.txt	0	8	out	RP	(PRT*)	-	-	-	-	*	-
en_2590.txt	0	9	to	TO	(S(VP*	-	-	-	-	*	-
en_2590.txt	0	10	be	VB	(VP*	-	-	-	-	*	-
en_2590.txt	0	11	little	RB	(ADJP(ADJP*	-	-	-	-	*	-
en_2590.txt	0	12	more	JJR	*)	-	-	-	-	*	-
en_2590.txt	0	13	than	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	14	a	DT	(NP*	-	-	-	-	*	-
en_2590.txt	0	15	fantasy	NN	*)))))))	-	-	-	-	*	-
en_2590.txt	0	16	?	.	*))	-	-	-	-	*	-

en_2590.txt	0	0	The	DT	(TOP(S(NP*	-	-	-	-	*	(1
en_2590.txt	0	1	problem	NN	*)	-	-	-	-	*	1)
en_2590.txt	0	2	largely	RB	(ADVP*)	-	-	-	-	*	-
en_2590.txt	0	3	comes	VBZ	(VP*	-	-	-	-	*	-
en_2590.txt	0	4	down	RP	(PRT*)	-	-	-	-	*	-
en_2590.txt	0	5	to	TO	(PP*	-	-	-	-	*	-
en_2590.txt	0	6	a	DT	(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	7	decrease	NN	*)	-	-	-	-	*	-
en_2590.txt	0	8	in	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	9	biomedical	JJ	(NP*	-	-	-	-	*	-
en_2590.txt	0	10	research-and-development	NN	*	-	-	-	-	*	-
en_2590.txt	0	11	expenditure	NN	*)))))	-	-	-	-	*	-
en_2590.txt	0	12	.	.	*))	-	-	-	-	*	-

en_2590.txt	0	0	As	IN	(TOP(S(SBAR*	-	-	-	-	*	-
en_2590.txt	0	1	it	PRP	(S(NP*)	-	-	-	-	*	(1)
en_2590.txt	0	2	stands	VBZ	(VP*)))	-	-	-	-	*	-
en_2590.txt	0	3	,	,	*	-	-	-	-	*	-
en_2590.txt	0	4	roughly	RB	(NP(QP*	-	-	-	-	*	-
en_2590.txt	0	5	$	$	*	-	-	-	-	*	-
en_2590.txt	0	6	270	CD	*	-	-	-	-	*	-
en_2590.txt	0	7	billion	CD	*))	-	-	-	-	*	-
en_2590.txt	0	8	is	VBZ	(VP*	-	-	-	-	*	-
en_2590.txt	0	9	invested	VBN	(VP*	-	-	-	-	*	-
en_2590.txt	0	10	in	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	11	the	DT	(NP*	-	-	-	-	*	-
en_2590.txt	0	12	field	NN	*))	-	-	-	-	*	-
en_2590.txt	0	13	each	DT	(NP*	-	-	-	-	*	-
en_2590.txt	0	14	year	NN	*)	-	-	-	-	*	-
en_2590.txt	0	15	,	,	*	-	-	-	-	*	-
en_2590.txt	0	16	producing	VBG	(S(VP*	-	-	-	-	*	-
en_2590.txt	0	17	an	DT	(NP*	-	-	-	-	*	-
en_2590.txt	0	18	impressive	JJ	*	-	-	-	-	*	-
en_2590.txt	0	19	half-million	JJ	*	-	-	-	-	*	-
en_2590.txt	0	20	research	NN	(NX(NX*	-	-	-	-	*	-
en_2590.txt	0	21	publications	NNS	*)	-	-	-	-	*	-
en_2590.txt	0	22	,	,	*	-	-	-	-	*	-
en_2590.txt	0	23	but	CC	*	-	-	-	-	*	-
en_2590.txt	0	24	only	RB	(NX*	-	-	-	-	*	-
en_2590.txt	0	25	20-30	CD	*))	-	-	-	-	*	-
en_2590.txt	0	26	new	JJ	(NP*	-	-	-	-	*	-
en_2590.txt	0	27	medicines	NNS	*))))))	-	-	-	-	*	-
en_2590.txt	0	28	.	.	*))	-	-	-	-	*	-

en_2590.txt	0	0	The	DT	(TOP(S(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	1	discrepancy	NN	*)	-	-	-	-	*	-
en_2590.txt	0	2	between	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	3	spending	NN	(NP*	-	-	-	-	*	-
en_2590.txt	0	4	and	CC	*	-	-	-	-	*	-
en_2590.txt	0	5	output	NN	*	-	-	-	-	*	-
en_2590.txt	0	6	adheres	NNS	*))	-	-	-	-	*	-
en_2590.txt	0	7	to	TO	(PP*	-	-	-	-	*	-
en_2590.txt	0	8	what	WP	(SBAR(WHNP*)	-	-	-	-	*	-
en_2590.txt	0	9	has	VBZ	(S(VP*	-	-	-	-	*	-
en_2590.txt	0	10	come	VBN	(VP*	-	-	-	-	*	-
en_2590.txt	0	11	to	TO	(S(VP*	-	-	-	-	*	-
en_2590.txt	0	12	be	VB	(VP*	-	-	-	-	*	-
en_2590.txt	0	13	known	VBN	(VP*	-	-	-	-	*	-
en_2590.txt	0	14	as	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	15	``	``	*	-	-	-	-	*	-
en_2590.txt	0	16	Eroom	NNP	(NP(NP*	-	-	-	-	*	(2|(3
en_2590.txt	0	17	'	POS	*)	-	-	-	-	*	2)
en_2590.txt	0	18	s	JJ	*	-	-	-	-	*	-
en_2590.txt	0	19	law	NN	*)	-	-	-	-	*	3)
en_2590.txt	0	20	''	''	*)))))))))))	-	-	-	-	*	-
en_2590.txt	0	21	–	SYM	(VP*	-	-	-	-	*	-
en_2590.txt	0	22	Moore	NNP	(NP(NP(NP*	-	-	-	-	*	(4
en_2590.txt	0	23	'	POS	*)	-	-	-	-	*	4)
en_2590.txt	0	24	s	JJ	*	-	-	-	-	*	-
en_2590.txt	0	25	law	NN	*)	-	-	-	-	*	-
en_2590.txt	0	26	in	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	27	reverse	NN	(NP*))))	-	-	-	-	*	-
en_2590.txt	0	28	.	.	*))	-	-	-	-	*	-

en_2590.txt	0	0	Moore	NNP	(TOP(S(NP(NP*	-	-	-	-	*	(4
en_2590.txt	0	1	'	POS	*)	-	-	-	-	*	4)
en_2590.txt	0	2	s	JJ	*	-	-	-	-	*	-
en_2590.txt	0	3	law	NN	*)	-	-	-	-	*	-
en_2590.txt	0	4	observes	VBZ	(VP*	-	-	-	-	*	-
en_2590.txt	0	5	the	DT	(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	6	increase	NN	*)	-	-	-	-	*	-
en_2590.txt	0	7	in	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	8	computer	NN	(NP*	-	-	-	-	*	-
en_2590.txt	0	9	processing	NN	*	-	-	-	-	*	-
en_2590.txt	0	10	power	NN	*)))	-	-	-	-	*	-
en_2590.txt	0	11	over	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	12	time	NN	(NP*))	-	-	-	-	*	-
en_2590.txt	0	13	–	SYM	(X*)	-	-	-	-	*	-
en_2590.txt	0	14	specifically	RB	(ADVP*)	-	-	-	-	*	-
en_2590.txt	0	15	,	,	*	-	-	-	-	*	-
en_2590.txt	0	16	that	IN	(SBAR*	-	-	-	-	*	-
en_2590.txt	0	17	the	DT	(S(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	18	number	NN	*)	-	-	-	-	*	-
en_2590.txt	0	19	of	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	20	transistors	NNS	(NP(NP*)	-	-	-	-	*	-
en_2590.txt	0	21	that	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_2590.txt	0	22	can	MD	(S(VP*	-	-	-	-	*	-
en_2590.txt	0	23	be	VB	(VP*	-	-	-	-	*	-
en_2590.txt	0	24	placed	VBN	(VP*	-	-	-	-	*	-
en_2590.txt	0	25	cheaply	RB	(ADVP*)	-	-	-	-	*	-
en_2590.txt	0	26	on	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	27	an	DT	(NP*	-	-	-	-	*	-
en_2590.txt	0	28	integrated	VBN	*	-	-	-	-	*	-
en_2590.txt	0	29	circuit	NN	*))))))))))	-	-	-	-	*	-
en_2590.txt	0	30	doubles	VBZ	(VP*	-	-	-	-	*	-
en_2590.txt	0	31	every	DT	(NP*	-	-	-	-	*	-
en_2590.txt	0	32	18-24	CD	*	-	-	-	-	*	-
en_2590.txt	0	33	months	NNS	*)))))	-	-	-	-	*	-
en_2590.txt	0	34	.	.	*))	-	-	-	-	*	-

en_2590.txt	0	0	By	IN	(TOP(S(PP*	-	-	-	-	*	-
en_2590.txt	0	1	contrast	NN	(NP*))	-	-	-	-	*	-
en_2590.txt	0	2	,	,	*	-	-	-	-	*	-
en_2590.txt	0	3	Eroom	NNP	(NP(NP*	-	-	-	-	*	(2|(3
en_2590.txt	0	4	'	POS	*)	-	-	-	-	*	2)
en_2590.txt	0	5	s	NNP	*	-	-	-	-	*	-
en_2590.txt	0	6	law	NN	*)	-	-	-	-	*	3)
en_2590.txt	0	7	charts	VBD	(VP*	-	-	-	-	*	-
en_2590.txt	0	8	the	DT	(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	9	regress	NN	*)	-	-	-	-	*	-
en_2590.txt	0	10	in	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	11	new	JJ	(NP*	-	-	-	-	*	-
en_2590.txt	0	12	drug	NN	*	-	-	-	-	*	-
en_2590.txt	0	13	approvals	NNS	*)))	-	-	-	-	*	-
en_2590.txt	0	14	,	,	*	-	-	-	-	*	-
en_2590.txt	0	15	noting	VBG	(S(VP*	-	-	-	-	*	-
en_2590.txt	0	16	that	IN	(SBAR*	-	-	-	-	*	-
en_2590.txt	0	17	the	DT	(S(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	18	costs	NNS	*)	-	-	-	-	*	-
en_2590.txt	0	19	of	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	20	developing	VBG	(S(VP*	-	-	-	-	*	-
en_2590.txt	0	21	a	DT	(NP*	-	-	-	-	*	-
en_2590.txt	0	22	new	JJ	*	-	-	-	-	*	-
en_2590.txt	0	23	medicine	NN	*)))))	-	-	-	-	*	-
en_2590.txt	0	24	double	VBP	(VP*	-	-	-	-	*	-
en_2590.txt	0	25	roughly	RB	(NP*	-	-	-	-	*	-
en_2590.txt	0	26	every	DT	*	-	-	-	-	*	-
en_2590.txt	0	27	nine	CD	*	-	-	-	-	*	-
en_2590.txt	0	28	years	NNS	*)))))))	-	-	-	-	*	-
en_2590.txt	0	29	.	.	*))	-	-	-	-	*	-

en_2590.txt	0	0	This	DT	(TOP(S(NP*	-	-	-	-	*	-
en_2590.txt	0	1	phenomenon	NN	*)	-	-	-	-	*	-
en_2590.txt	0	2	is	VBZ	(VP*	-	-	-	-	*	-
en_2590.txt	0	3	rooted	VBN	(VP*	-	-	-	-	*	-
en_2590.txt	0	4	in	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	5	high	JJ	(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	6	rates	NNS	*)	-	-	-	-	*	-
en_2590.txt	0	7	of	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	8	drug	NN	(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	9	failure	NN	*)	-	-	-	-	*	-
en_2590.txt	0	10	and	CC	*	-	-	-	-	*	-
en_2590.txt	0	11	lengthening	VBG	(NP*	-	-	-	-	*	-
en_2590.txt	0	12	technology	NN	*	-	-	-	-	*	-
en_2590.txt	0	13	cycles	NNS	*)))))))	-	-	-	-	*	-
en_2590.txt	0	14	.	.	*))	-	-	-	-	*	-

en_2590.txt	0	0	The	DT	(TOP(S(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	1	probability	NN	*)	-	-	-	-	*	-
en_2590.txt	0	2	that	IN	(SBAR*	-	-	-	-	*	-
en_2590.txt	0	3	a	DT	(S(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	4	drug	NN	*)	-	-	-	-	*	-
en_2590.txt	0	5	entering	VBG	(VP*	-	-	-	-	*	-
en_2590.txt	0	6	clinical	JJ	(NP*	-	-	-	-	*	-
en_2590.txt	0	7	trials	NNS	*)))	-	-	-	-	*	-
en_2590.txt	0	8	will	MD	(VP*	-	-	-	-	*	-
en_2590.txt	0	9	gain	VB	(VP*	-	-	-	-	*	-
en_2590.txt	0	10	approval	NN	(NP(NP*)	-	-	-	-	*	-
en_2590.txt	0	11	from	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	12	the	DT	(NP*	-	-	-	-	*	(5
en_2590.txt	0	13	US	NNP	*	-	-	-	-	*	-
en_2590.txt	0	14	Food	NNP	*	-	-	-	-	*	-
en_2590.txt	0	15	and	CC	*	-	-	-	-	*	-
en_2590.txt	0	16	Drug	NNP	*	-	-	-	-	*	-
en_2590.txt	0	17	Administration	NNP	*))))))))	-	-	-	-	*	5)
en_2590.txt	0	18	has	VBZ	(VP*	-	-	-	-	*	-
en_2590.txt	0	19	dropped	VBN	(VP*	-	-	-	-	*	-
en_2590.txt	0	20	from	IN	(PP(PP*	-	-	-	-	*	-
en_2590.txt	0	21	23.9	CD	(NP*	-	-	-	-	*	-
en_2590.txt	0	22	%	NN	*)	-	-	-	-	*	-
en_2590.txt	0	23	in	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	24	1997	CD	(NP*)))	-	-	-	-	*	-
en_2590.txt	0	25	to	TO	(PP*	-	-	-	-	*	-
en_2590.txt	0	26	10.4	CD	(NP*	-	-	-	-	*	-
en_2590.txt	0	27	%	NN	*)	-	-	-	-	*	-
en_2590.txt	0	28	today	NN	(NP*)))))	-	-	-	-	*	(6)
en_2590.txt	0	29	.	.	*))	-	-	-	-	*	-

en_2590.txt	0	0	While	IN	(TOP(S(SBAR*	-	-	-	-	*	-
en_2590.txt	0	1	the	DT	(S(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	2	first	JJ	*	-	-	-	-	*	-
en_2590.txt	0	3	recombinant	JJ	*	-	-	-	-	*	-
en_2590.txt	0	4	insulin	NN	*)	-	-	-	-	*	-
en_2590.txt	0	5	in	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	6	the	DT	(NP(NP*	-	-	-	-	*	(7
en_2590.txt	0	7	1980	CD	*	-	-	-	-	*	-
en_2590.txt	0	8	'	POS	*)	-	-	-	-	*	-
en_2590.txt	0	9	s	NN	*)))	-	-	-	-	*	7)
en_2590.txt	0	10	took	VBD	(VP*	-	-	-	-	*	-
en_2590.txt	0	11	less	JJR	(NP(QP*	-	-	-	-	*	-
en_2590.txt	0	12	than	IN	*	-	-	-	-	*	-
en_2590.txt	0	13	a	DT	*)	-	-	-	-	*	-
en_2590.txt	0	14	decade	NN	*)	-	-	-	-	*	-
en_2590.txt	0	15	from	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	16	testing	VBG	(S(VP*	-	-	-	-	*	-
en_2590.txt	0	17	to	TO	(PP*	-	-	-	-	*	-
en_2590.txt	0	18	approval	NN	(NP*))))))))	-	-	-	-	*	-
en_2590.txt	0	19	,	,	*	-	-	-	-	*	-
en_2590.txt	0	20	monoclonal	JJ	(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	21	antibodies	NNS	*)	-	-	-	-	*	-
en_2590.txt	0	22	and	CC	*	-	-	-	-	*	-
en_2590.txt	0	23	gene	NN	(NP*	-	-	-	-	*	-
en_2590.txt	0	24	therapy	NN	*))	-	-	-	-	*	-
en_2590.txt	0	25	took	VBD	(VP*	-	-	-	-	*	-
en_2590.txt	0	26	more	JJR	(NP(NP(QP*	-	-	-	-	*	-
en_2590.txt	0	27	than	IN	*	-	-	-	-	*	-
en_2590.txt	0	28	20	CD	*)	-	-	-	-	*	-
en_2590.txt	0	29	years	NNS	*)	-	-	-	-	*	-
en_2590.txt	0	30	to	TO	(SBAR(S(VP*	-	-	-	-	*	-
en_2590.txt	0	31	reach	VB	(VP*	-	-	-	-	*	-
en_2590.txt	0	32	the	DT	(NP*	-	-	-	-	*	-
en_2590.txt	0	33	same	JJ	*	-	-	-	-	*	-
en_2590.txt	0	34	milestone	NN	*)))))))	-	-	-	-	*	-
en_2590.txt	0	35	.	.	*))	-	-	-	-	*	-

en_2590.txt	0	0	So	RB	(TOP(S(ADVP*	-	-	-	-	*	-
en_2590.txt	0	1	far	RB	*)	-	-	-	-	*	-
en_2590.txt	0	2	,	,	*	-	-	-	-	*	-
en_2590.txt	0	3	pharmaceutical	JJ	(NP(ADJP*	-	-	-	-	*	(8
en_2590.txt	0	4	and	CC	*	-	-	-	-	*	-
en_2590.txt	0	5	biomedical	JJ	*)	-	-	-	-	*	-
en_2590.txt	0	6	research	NN	*	-	-	-	-	*	-
en_2590.txt	0	7	firms	NNS	*)	-	-	-	-	*	8)
en_2590.txt	0	8	have	VBP	(VP*	-	-	-	-	*	-
en_2590.txt	0	9	responded	VBN	(VP*	-	-	-	-	*	-
en_2590.txt	0	10	to	TO	(PP*	-	-	-	-	*	-
en_2590.txt	0	11	Eroom	NNP	(NP(NP*	-	-	-	-	*	(2|(3
en_2590.txt	0	12	'	POS	*)	-	-	-	-	*	2)
en_2590.txt	0	13	s	JJ	*	-	-	-	-	*	-
en_2590.txt	0	14	law	NN	*))	-	-	-	-	*	3)
en_2590.txt	0	15	by	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	16	cutting	VBG	(S(VP(VP*	-	-	-	-	*	-
en_2590.txt	0	17	R	NNP	(NP*	-	-	-	-	*	-
en_2590.txt	0	18	&	CC	*	-	-	-	-	*	-
en_2590.txt	0	19	D	NNP	*))	-	-	-	-	*	-
en_2590.txt	0	20	or	CC	*	-	-	-	-	*	-
en_2590.txt	0	21	moving	VBG	(VP(VP*	-	-	-	-	*	-
en_2590.txt	0	22	it	PRP	(NP*)	-	-	-	-	*	(3)
en_2590.txt	0	23	to	TO	(PP*	-	-	-	-	*	-
en_2590.txt	0	24	less	RBR	(NP(NP(ADJP*	-	-	-	-	*	-
en_2590.txt	0	25	expensive	JJ	*)	-	-	-	-	*	-
en_2590.txt	0	26	sites	NNS	*)	-	-	-	-	*	-
en_2590.txt	0	27	in	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	28	Asia	NNP	(NP*)))))	-	-	-	-	*	(9)
en_2590.txt	0	29	,	,	*	-	-	-	-	*	-
en_2590.txt	0	30	shifting	VBG	(VP*	-	-	-	-	*	-
en_2590.txt	0	31	their	PRP$	(NP*	-	-	-	-	*	(8)
en_2590.txt	0	32	focus	NN	*)	-	-	-	-	*	-
en_2590.txt	0	33	to	TO	(PP*	-	-	-	-	*	-
en_2590.txt	0	34	less	RBR	(NP(ADJP*	-	-	-	-	*	-
en_2590.txt	0	35	prevalent	JJ	*)	-	-	-	-	*	-
en_2590.txt	0	36	diseases	NNS	*)))	-	-	-	-	*	-
en_2590.txt	0	37	,	,	*	-	-	-	-	*	-
en_2590.txt	0	38	and	CC	*	-	-	-	-	*	-
en_2590.txt	0	39	sourcing	VBG	(VP*	-	-	-	-	*	-
en_2590.txt	0	40	innovation	NN	(NP*)	-	-	-	-	*	-
en_2590.txt	0	41	externally	RB	(ADVP*))))))))	-	-	-	-	*	-
en_2590.txt	0	42	.	.	*))	-	-	-	-	*	-

en_2590.txt	0	0	As	IN	(TOP(S(PP*	-	-	-	-	*	-
en_2590.txt	0	1	a	DT	(NP*	-	-	-	-	*	-
en_2590.txt	0	2	result	NN	*))	-	-	-	-	*	-
en_2590.txt	0	3	,	,	*	-	-	-	-	*	-
en_2590.txt	0	4	growth	NN	(NP(NP*)	-	-	-	-	*	-
en_2590.txt	0	5	in	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	6	biomedical	JJ	(NP*	-	-	-	-	*	-
en_2590.txt	0	7	R	NN	*	-	-	-	-	*	-
en_2590.txt	0	8	&	CC	*	-	-	-	-	*	-
en_2590.txt	0	9	D	NNP	*	-	-	-	-	*	-
en_2590.txt	0	10	spending	NN	*)))	-	-	-	-	*	-
en_2590.txt	0	11	has	VBZ	(VP*	-	-	-	-	*	-
en_2590.txt	0	12	declined	VBN	(VP*	-	-	-	-	*	-
en_2590.txt	0	13	from	IN	(PP(PP*	-	-	-	-	*	-
en_2590.txt	0	14	more	JJR	(NP(NP(QP*	-	-	-	-	*	-
en_2590.txt	0	15	than	IN	*	-	-	-	-	*	-
en_2590.txt	0	16	9	CD	*)	-	-	-	-	*	-
en_2590.txt	0	17	%	NN	*)	-	-	-	-	*	-
en_2590.txt	0	18	annually	RB	(ADVP*))	-	-	-	-	*	-
en_2590.txt	0	19	in	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	20	the	DT	(NP(NP*	-	-	-	-	*	(7
en_2590.txt	0	21	early	JJ	*	-	-	-	-	*	-
en_2590.txt	0	22	2000	CD	*	-	-	-	-	*	-
en_2590.txt	0	23	'	POS	*)	-	-	-	-	*	-
en_2590.txt	0	24	s	NN	*)))	-	-	-	-	*	7)
en_2590.txt	0	25	to	TO	(PP*	-	-	-	-	*	-
en_2590.txt	0	26	less	JJR	(NP(QP*	-	-	-	-	*	-
en_2590.txt	0	27	than	IN	*	-	-	-	-	*	-
en_2590.txt	0	28	3	CD	*)	-	-	-	-	*	-
en_2590.txt	0	29	%	NN	*)	-	-	-	-	*	-
en_2590.txt	0	30	today	NN	(NP*)))))	-	-	-	-	*	(6)
en_2590.txt	0	31	.	.	*))	-	-	-	-	*	-

en_2590.txt	0	0	But	CC	(TOP(S*	-	-	-	-	*	-
en_2590.txt	0	1	,	,	*	-	-	-	-	*	-
en_2590.txt	0	2	while	IN	(SBAR*	-	-	-	-	*	-
en_2590.txt	0	3	this	DT	(S(NP*	-	-	-	-	*	(10
en_2590.txt	0	4	strategy	NN	*)	-	-	-	-	*	10)
en_2590.txt	0	5	will	MD	(VP*	-	-	-	-	*	-
en_2590.txt	0	6	moderate	VB	(VP*	-	-	-	-	*	-
en_2590.txt	0	7	the	DT	(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	8	impact	NN	*)	-	-	-	-	*	-
en_2590.txt	0	9	of	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	10	Eroom	NNP	(NP(NP*	-	-	-	-	*	(2|(3
en_2590.txt	0	11	'	POS	*)	-	-	-	-	*	2)
en_2590.txt	0	12	s	JJ	*	-	-	-	-	*	-
en_2590.txt	0	13	law	NN	*)))))))	-	-	-	-	*	3)
en_2590.txt	0	14	,	,	*	-	-	-	-	*	-
en_2590.txt	0	15	it	PRP	(NP*)	-	-	-	-	*	(10)
en_2590.txt	0	16	will	MD	(VP*	-	-	-	-	*	-
en_2590.txt	0	17	ultimately	RB	(ADVP*)	-	-	-	-	*	-
en_2590.txt	0	18	prove	VB	(VP*	-	-	-	-	*	-
en_2590.txt	0	19	inadequate	JJ	(ADJP*)	-	-	-	-	*	-
en_2590.txt	0	20	to	TO	(S(VP*	-	-	-	-	*	-
en_2590.txt	0	21	sustain	VB	(VP*	-	-	-	-	*	-
en_2590.txt	0	22	the	DT	(NP*	-	-	-	-	*	(11
en_2590.txt	0	23	industry	NN	*))))))	-	-	-	-	*	11)
en_2590.txt	0	24	.	.	*))	-	-	-	-	*	-

en_2590.txt	0	0	The	DT	(TOP(S(NP(NP*	-	-	-	-	*	(11
en_2590.txt	0	1	industry	NN	*	-	-	-	-	*	-
en_2590.txt	0	2	'	POS	*)	-	-	-	-	*	11)
en_2590.txt	0	3	s	JJ	*	-	-	-	-	*	-
en_2590.txt	0	4	ability	NN	*	-	-	-	-	*	-
en_2590.txt	0	5	to	TO	(S(VP*	-	-	-	-	*	-
en_2590.txt	0	6	support	VB	(VP*	-	-	-	-	*	-
en_2590.txt	0	7	R	NN	(NP*	-	-	-	-	*	-
en_2590.txt	0	8	&	CC	*	-	-	-	-	*	-
en_2590.txt	0	9	D	NNP	*	-	-	-	-	*	-
en_2590.txt	0	10	budgets	NNS	*)))))	-	-	-	-	*	-
en_2590.txt	0	11	has	VBZ	(VP*	-	-	-	-	*	-
en_2590.txt	0	12	already	RB	(ADVP*)	-	-	-	-	*	-
en_2590.txt	0	13	led	VBN	(VP*	-	-	-	-	*	-
en_2590.txt	0	14	to	TO	(PP*	-	-	-	-	*	-
en_2590.txt	0	15	the	DT	(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	16	closure	NN	*)	-	-	-	-	*	-
en_2590.txt	0	17	of	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	18	more	JJR	(NP(QP*	-	-	-	-	*	-
en_2590.txt	0	19	than	IN	*	-	-	-	-	*	-
en_2590.txt	0	20	30	CD	*)	-	-	-	-	*	-
en_2590.txt	0	21	major	JJ	*	-	-	-	-	*	-
en_2590.txt	0	22	research	NN	*	-	-	-	-	*	-
en_2590.txt	0	23	sites	NNS	*))))))	-	-	-	-	*	-
en_2590.txt	0	24	.	.	*))	-	-	-	-	*	-

en_2590.txt	0	0	The	DT	(TOP(S(NP*	-	-	-	-	*	-
en_2590.txt	0	1	United	NNP	*	-	-	-	-	*	-
en_2590.txt	0	2	States	NNPS	*)	-	-	-	-	*	-
en_2590.txt	0	3	bore	VBD	(VP*	-	-	-	-	*	-
en_2590.txt	0	4	the	DT	(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	5	brunt	NN	*)	-	-	-	-	*	-
en_2590.txt	0	6	of	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	7	these	DT	(NP*	-	-	-	-	*	-
en_2590.txt	0	8	closures	NNS	*)))	-	-	-	-	*	-
en_2590.txt	0	9	,	,	*	-	-	-	-	*	-
en_2590.txt	0	10	with	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	11	biomedical	JJ	(S(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	12	R	NN	*)	-	-	-	-	*	-
en_2590.txt	0	13	&	CC	*	-	-	-	-	*	-
en_2590.txt	0	14	D	NNP	*	-	-	-	-	*	-
en_2590.txt	0	15	expenditure	NN	*)	-	-	-	-	*	-
en_2590.txt	0	16	declining	VBG	(VP*	-	-	-	-	*	-
en_2590.txt	0	17	by	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	18	more	JJR	(NP(QP*	-	-	-	-	*	-
en_2590.txt	0	19	than	IN	*	-	-	-	-	*	-
en_2590.txt	0	20	$	$	*	-	-	-	-	*	-
en_2590.txt	0	21	12	CD	*	-	-	-	-	*	-
en_2590.txt	0	22	billion	CD	*)))	-	-	-	-	*	-
en_2590.txt	0	23	from	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	24	2007	CD	(NP(NP*)	-	-	-	-	*	-
en_2590.txt	0	25	to	TO	(PP*	-	-	-	-	*	-
en_2590.txt	0	26	2012	CD	(NP*))))))))	-	-	-	-	*	-
en_2590.txt	0	27	.	.	*))	-	-	-	-	*	-

en_2590.txt	0	0	And	CC	(TOP(X*	-	-	-	-	*	-
en_2590.txt	0	1	Asia	NNP	(NP*)	-	-	-	-	*	(9)
en_2590.txt	0	2	–	SYM	(X*)	-	-	-	-	*	-
en_2590.txt	0	3	where	WRB	(SBAR(WHADVP*)	-	-	-	-	*	-
en_2590.txt	0	4	biomedical	JJ	(S(NP*	-	-	-	-	*	-
en_2590.txt	0	5	R	NN	*	-	-	-	-	*	-
en_2590.txt	0	6	&	CC	*	-	-	-	-	*	-
en_2590.txt	0	7	D	NNP	*)	-	-	-	-	*	-
en_2590.txt	0	8	is	VBZ	(VP*	-	-	-	-	*	-
en_2590.txt	0	9	growing	VBG	(VP*	-	-	-	-	*	-
en_2590.txt	0	10	rapidly	RB	(ADVP*)	-	-	-	-	*	-
en_2590.txt	0	11	,	,	*	-	-	-	-	*	-
en_2590.txt	0	12	but	CC	(PP*	-	-	-	-	*	-
en_2590.txt	0	13	from	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	14	a	DT	(NP*	-	-	-	-	*	-
en_2590.txt	0	15	small	JJ	*	-	-	-	-	*	-
en_2590.txt	0	16	base	NN	*)))))))	-	-	-	-	*	-
en_2590.txt	0	17	–	SYM	(X*)	-	-	-	-	*	-
en_2590.txt	0	18	is	VBZ	(X(VP*	-	-	-	-	*	-
en_2590.txt	0	19	unlikely	JJ	(ADJP*	-	-	-	-	*	-
en_2590.txt	0	20	to	TO	(S(VP*	-	-	-	-	*	-
en_2590.txt	0	21	pick	VB	(VP*	-	-	-	-	*	-
en_2590.txt	0	22	up	RP	(PRT*)	-	-	-	-	*	-
en_2590.txt	0	23	the	DT	(NP*	-	-	-	-	*	-
en_2590.txt	0	24	slack	NN	*)))))))	-	-	-	-	*	-
en_2590.txt	0	25	.	.	*))	-	-	-	-	*	-

en_2590.txt	0	0	Asian	JJ	(TOP(S(S(NP*	-	-	-	-	*	(12
en_2590.txt	0	1	countries	NNS	*)	-	-	-	-	*	12)
en_2590.txt	0	2	have	VBP	(VP*	-	-	-	-	*	-
en_2590.txt	0	3	tended	VBN	(VP*	-	-	-	-	*	-
en_2590.txt	0	4	to	TO	(S(VP*	-	-	-	-	*	-
en_2590.txt	0	5	be	VB	(VP*	-	-	-	-	*	-
en_2590.txt	0	6	reluctant	JJ	(ADJP*	-	-	-	-	*	-
en_2590.txt	0	7	to	TO	(S(VP*	-	-	-	-	*	-
en_2590.txt	0	8	shoulder	VB	(VP*	-	-	-	-	*	-
en_2590.txt	0	9	the	DT	(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	10	cost	NN	*)	-	-	-	-	*	-
en_2590.txt	0	11	of	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	12	developing	VBG	(S(VP*	-	-	-	-	*	-
en_2590.txt	0	13	new	JJ	(NP*	-	-	-	-	*	-
en_2590.txt	0	14	medicines	NNS	*)))))))))	-	-	-	-	*	-
en_2590.txt	0	15	,	,	*	-	-	-	-	*	-
en_2590.txt	0	16	with	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	17	reimbursements	NNS	(NP(NP*)	-	-	-	-	*	-
en_2590.txt	0	18	falling	VBG	(VP*	-	-	-	-	*	-
en_2590.txt	0	19	far	RB	(ADVP*	-	-	-	-	*	-
en_2590.txt	0	20	short	JJ	*	-	-	-	-	*	-
en_2590.txt	0	21	of	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	22	US	NNP	(NP*	-	-	-	-	*	-
en_2590.txt	0	23	levels	NNS	*))))))))))))	-	-	-	-	*	-
en_2590.txt	0	24	,	,	*	-	-	-	-	*	-
en_2590.txt	0	25	and	CC	*	-	-	-	-	*	-
en_2590.txt	0	26	their	PRP$	(S(NP*	-	-	-	-	*	(12)
en_2590.txt	0	27	R	NN	*	-	-	-	-	*	-
en_2590.txt	0	28	&	CC	*	-	-	-	-	*	-
en_2590.txt	0	29	D	NNP	*	-	-	-	-	*	-
en_2590.txt	0	30	productivity	NN	*)	-	-	-	-	*	-
en_2590.txt	0	31	will	MD	(VP*	-	-	-	-	*	-
en_2590.txt	0	32	not	RB	*	-	-	-	-	*	-
en_2590.txt	0	33	match	VB	(VP*	-	-	-	-	*	-
en_2590.txt	0	34	that	DT	(NP(NP*)	-	-	-	-	*	-
en_2590.txt	0	35	of	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	36	the	DT	(NP(NP(NP*	-	-	-	-	*	(5
en_2590.txt	0	37	US	NNP	*)	-	-	-	-	*	5)
en_2590.txt	0	38	and	CC	*	-	-	-	-	*	-
en_2590.txt	0	39	Europe	NNP	*)	-	-	-	-	*	-
en_2590.txt	0	40	for	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	41	several	JJ	(NP(ADJP*	-	-	-	-	*	-
en_2590.txt	0	42	more	JJR	*)	-	-	-	-	*	-
en_2590.txt	0	43	years	NNS	*))))))))	-	-	-	-	*	-
en_2590.txt	0	44	.	.	*))	-	-	-	-	*	-

en_2590.txt	0	0	Moreover	RB	(TOP(S(ADVP*)	-	-	-	-	*	-
en_2590.txt	0	1	,	,	*	-	-	-	-	*	-
en_2590.txt	0	2	biomedical	JJ	(NP*	-	-	-	-	*	(13
en_2590.txt	0	3	research	NN	*	-	-	-	-	*	-
en_2590.txt	0	4	firms	NNS	*)	-	-	-	-	*	13)
en_2590.txt	0	5	are	VBP	(VP*	-	-	-	-	*	-
en_2590.txt	0	6	abandoning	VBG	(VP*	-	-	-	-	*	-
en_2590.txt	0	7	certain	JJ	(NP*	-	-	-	-	*	-
en_2590.txt	0	8	diseases	NNS	*)	-	-	-	-	*	-
en_2590.txt	0	9	in	IN	(SBAR*	-	-	-	-	*	-
en_2590.txt	0	10	order	NN	*	-	-	-	-	*	-
en_2590.txt	0	11	to	TO	(S(VP*	-	-	-	-	*	-
en_2590.txt	0	12	avoid	VB	(VP*	-	-	-	-	*	-
en_2590.txt	0	13	the	DT	(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	14	large-scale	JJ	*	-	-	-	-	*	-
en_2590.txt	0	15	trials	NNS	*)	-	-	-	-	*	-
en_2590.txt	0	16	that	IN	(SBAR(WHNP*)	-	-	-	-	*	-
en_2590.txt	0	17	they	PRP	(S(NP*)	-	-	-	-	*	(13)
en_2590.txt	0	18	require	VBP	(VP*	-	-	-	-	*	-
en_2590.txt	0	19	,	,	*	-	-	-	-	*	-
en_2590.txt	0	20	focusing	VBG	(S(VP*	-	-	-	-	*	-
en_2590.txt	0	21	instead	RB	(PP*	-	-	-	-	*	-
en_2590.txt	0	22	on	IN	*	-	-	-	-	*	-
en_2590.txt	0	23	``	``	(NP*	-	-	-	-	*	-
en_2590.txt	0	24	orphan	JJ	(NP*	-	-	-	-	*	-
en_2590.txt	0	25	diseases	NNS	*)	-	-	-	-	*	-
en_2590.txt	0	26	''	''	*	-	-	-	-	*	-
en_2590.txt	0	27	like	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	28	cystic	NN	(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	29	fibrosis	NN	*)	-	-	-	-	*	-
en_2590.txt	0	30	,	,	*	-	-	-	-	*	-
en_2590.txt	0	31	which	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_2590.txt	0	32	demand	VBP	(S(VP*	-	-	-	-	*	-
en_2590.txt	0	33	smaller	JJR	(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	34	clinical	JJ	*	-	-	-	-	*	-
en_2590.txt	0	35	trials	NNS	*)	-	-	-	-	*	-
en_2590.txt	0	36	that	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_2590.txt	0	37	have	VBP	(S(VP*	-	-	-	-	*	-
en_2590.txt	0	38	a	DT	(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	39	higher	JJR	*	-	-	-	-	*	-
en_2590.txt	0	40	probability	NN	*)	-	-	-	-	*	-
en_2590.txt	0	41	of	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	42	success	NN	(NP*))	-	-	-	-	*	-
en_2590.txt	0	43	,	,	*	-	-	-	-	*	-
en_2590.txt	0	44	leading	VBG	(VP*	-	-	-	-	*	-
en_2590.txt	0	45	to	TO	(PP*	-	-	-	-	*	-
en_2590.txt	0	46	drugs	NNS	(NP(NP*)	-	-	-	-	*	-
en_2590.txt	0	47	that	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_2590.txt	0	48	can	MD	(S(VP*	-	-	-	-	*	-
en_2590.txt	0	49	cost	VB	(VP*	-	-	-	-	*	-
en_2590.txt	0	50	more	JJR	(NP(QP*	-	-	-	-	*	-
en_2590.txt	0	51	than	IN	*	-	-	-	-	*	-
en_2590.txt	0	52	$	$	*	-	-	-	-	*	-
en_2590.txt	0	53	100,000	CD	*))))))))))))))	-	-	-	-	*	-
en_2590.txt	0	54	annually	RB	(ADVP*	-	-	-	-	*	-
en_2590.txt	0	55	per	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	56	patient	NN	(NP*))))))))))))))))))))))	-	-	-	-	*	-
en_2590.txt	0	57	.	.	*))	-	-	-	-	*	-

en_2590.txt	0	0	But	CC	(TOP(S*	-	-	-	-	*	-
en_2590.txt	0	1	,	,	*	-	-	-	-	*	-
en_2590.txt	0	2	with	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	3	insurers	NNS	(S(NP*	-	-	-	-	*	-
en_2590.txt	0	4	and	CC	*	-	-	-	-	*	-
en_2590.txt	0	5	payers	NNS	*)	-	-	-	-	*	-
en_2590.txt	0	6	worldwide	NN	(VP*	-	-	-	-	*	-
en_2590.txt	0	7	becoming	VBG	(VP*	-	-	-	-	*	-
en_2590.txt	0	8	increasingly	RB	(ADJP*	-	-	-	-	*	-
en_2590.txt	0	9	vigilant	JJ	*	-	-	-	-	*	-
en_2590.txt	0	10	about	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	11	controlling	VBG	(NP*	-	-	-	-	*	-
en_2590.txt	0	12	costs	NNS	*)))))))	-	-	-	-	*	-
en_2590.txt	0	13	,	,	*	-	-	-	-	*	-
en_2590.txt	0	14	this	DT	(NP*	-	-	-	-	*	-
en_2590.txt	0	15	business	NN	*	-	-	-	-	*	-
en_2590.txt	0	16	model	NN	*)	-	-	-	-	*	-
en_2590.txt	0	17	'	''	*	-	-	-	-	*	-
en_2590.txt	0	18	s	VBZ	(VP*	-	-	-	-	*	-
en_2590.txt	0	19	long-term	JJ	(SBAR(S(NP*	-	-	-	-	*	-
en_2590.txt	0	20	prospects	NNS	*)	-	-	-	-	*	-
en_2590.txt	0	21	are	VBP	(VP*	-	-	-	-	*	-
en_2590.txt	0	22	unclear	JJ	(ADJP*)))))	-	-	-	-	*	-
en_2590.txt	0	23	.	.	*))	-	-	-	-	*	-

en_2590.txt	0	0	Finally	RB	(TOP(S(ADVP*)	-	-	-	-	*	-
en_2590.txt	0	1	,	,	*	-	-	-	-	*	-
en_2590.txt	0	2	while	IN	(SBAR*	-	-	-	-	*	-
en_2590.txt	0	3	drugs	NNS	(S(NP*)	-	-	-	-	*	-
en_2590.txt	0	4	are	VBP	(VP*	-	-	-	-	*	-
en_2590.txt	0	5	increasingly	RB	(ADVP*)	-	-	-	-	*	-
en_2590.txt	0	6	produced	VBN	(VP*	-	-	-	-	*	-
en_2590.txt	0	7	by	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	8	small	JJ	(NP*	-	-	-	-	*	-
en_2590.txt	0	9	companies	NNS	*))	-	-	-	-	*	-
en_2590.txt	0	10	that	IN	(SBAR*	-	-	-	-	*	-
en_2590.txt	0	11	larger	JJR	(S(NP*	-	-	-	-	*	-
en_2590.txt	0	12	pharmaceutical	NN	*	-	-	-	-	*	-
en_2590.txt	0	13	firms	NNS	*)	-	-	-	-	*	-
en_2590.txt	0	14	then	RB	(ADVP*)	-	-	-	-	*	-
en_2590.txt	0	15	acquire	VB	(VP*)))))))	-	-	-	-	*	-
en_2590.txt	0	16	,	,	*	-	-	-	-	*	-
en_2590.txt	0	17	funding	NN	(NP(NP*)	-	-	-	-	*	-
en_2590.txt	0	18	for	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	19	these	DT	(NP*	-	-	-	-	*	-
en_2590.txt	0	20	start-ups	NNS	*)))	-	-	-	-	*	-
en_2590.txt	0	21	is	VBZ	(VP*	-	-	-	-	*	-
en_2590.txt	0	22	drying	VBG	(VP*	-	-	-	-	*	-
en_2590.txt	0	23	up	RP	(PRT*)))	-	-	-	-	*	-
en_2590.txt	0	24	.	.	*))	-	-	-	-	*	-

en_2590.txt	0	0	Likewise	RB	(TOP(X(ADVP*)	-	-	-	-	*	-
en_2590.txt	0	1	,	,	*	-	-	-	-	*	-
en_2590.txt	0	2	universities	NNS	*	-	-	-	-	*	-
en_2590.txt	0	3	–	SYM	(X*)	-	-	-	-	*	-
en_2590.txt	0	4	the	DT	(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	5	main	JJ	*	-	-	-	-	*	-
en_2590.txt	0	6	source	NN	*)	-	-	-	-	*	-
en_2590.txt	0	7	of	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	8	biomedical	JJ	(NP*	-	-	-	-	*	-
en_2590.txt	0	9	innovation	NN	*)))	-	-	-	-	*	-
en_2590.txt	0	10	–	SYM	(FRAG(X*)	-	-	-	-	*	-
en_2590.txt	0	11	are	VBP	(VP*	-	-	-	-	*	-
en_2590.txt	0	12	facing	VBG	(VP*	-	-	-	-	*	-
en_2590.txt	0	13	dwindling	VBG	(NP*	-	-	-	-	*	-
en_2590.txt	0	14	budgets	NNS	*))))	-	-	-	-	*	-
en_2590.txt	0	15	.	.	*))	-	-	-	-	*	-

en_2590.txt	0	0	This	DT	(TOP(FRAG(NP*	-	-	-	-	*	-
en_2590.txt	0	1	year	NN	*)	-	-	-	-	*	-
en_2590.txt	0	2	,	,	*	-	-	-	-	*	-
en_2590.txt	0	3	funding	NN	(NP(NP*)	-	-	-	-	*	-
en_2590.txt	0	4	for	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	5	the	DT	(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	6	US	NNP	*	-	-	-	-	*	-
en_2590.txt	0	7	National	NNP	*	-	-	-	-	*	-
en_2590.txt	0	8	Institutes	NNPS	*)	-	-	-	-	*	-
en_2590.txt	0	9	of	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	10	Health	NNP	(NP*))	-	-	-	-	*	-
en_2590.txt	0	11	-LRB-	-LRB-	(PRN*	-	-	-	-	*	-
en_2590.txt	0	12	NIH	NNP	(NP*)	-	-	-	-	*	-
en_2590.txt	0	13	-RRB-	-RRB-	*))))	-	-	-	-	*	-
en_2590.txt	0	14	–	SYM	(X*)	-	-	-	-	*	-
en_2590.txt	0	15	one	CD	(S(NP(NP*)	-	-	-	-	*	-
en_2590.txt	0	16	of	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	17	the	DT	(NP*	-	-	-	-	*	-
en_2590.txt	0	18	world	NN	*))	-	-	-	-	*	-
en_2590.txt	0	19	'	''	*)	-	-	-	-	*	-
en_2590.txt	0	20	s	VBZ	(VP*	-	-	-	-	*	-
en_2590.txt	0	21	leading	VBG	(NP*	-	-	-	-	*	-
en_2590.txt	0	22	medical	JJ	*	-	-	-	-	*	-
en_2590.txt	0	23	research	NN	*	-	-	-	-	*	-
en_2590.txt	0	24	centers	NNS	*)))	-	-	-	-	*	-
en_2590.txt	0	25	–	SYM	(X*)	-	-	-	-	*	-
en_2590.txt	0	26	is	VBZ	(VP*	-	-	-	-	*	-
en_2590.txt	0	27	a	DT	(ADJP(ADJP(NP(QP*	-	-	-	-	*	-
en_2590.txt	0	28	billion	CD	*)	-	-	-	-	*	-
en_2590.txt	0	29	dollars	NNS	*)	-	-	-	-	*	-
en_2590.txt	0	30	lower	JJR	*)	-	-	-	-	*	-
en_2590.txt	0	31	than	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	32	in	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	33	2012	CD	(NP*)))))	-	-	-	-	*	-
en_2590.txt	0	34	.	.	*))	-	-	-	-	*	-

en_2590.txt	0	0	Restoring	JJ	(TOP(S(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	1	funding	NN	*)	-	-	-	-	*	-
en_2590.txt	0	2	for	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	3	basic	JJ	(NP*	-	-	-	-	*	(14
en_2590.txt	0	4	biomedical	JJ	*	-	-	-	-	*	-
en_2590.txt	0	5	research	NN	*)))	-	-	-	-	*	14)
en_2590.txt	0	6	appears	VBZ	(VP*	-	-	-	-	*	-
en_2590.txt	0	7	to	TO	(S(VP*	-	-	-	-	*	-
en_2590.txt	0	8	have	VB	(VP*	-	-	-	-	*	-
en_2590.txt	0	9	lost	VBN	(VP*	-	-	-	-	*	-
en_2590.txt	0	10	favor	NN	(NP(NP*)	-	-	-	-	*	-
en_2590.txt	0	11	with	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	12	policymakers	NNS	(NP*)))	-	-	-	-	*	-
en_2590.txt	0	13	,	,	*	-	-	-	-	*	-
en_2590.txt	0	14	because	IN	(SBAR*	-	-	-	-	*	-
en_2590.txt	0	15	it	PRP	(S(NP*)	-	-	-	-	*	(14)
en_2590.txt	0	16	does	VBZ	(VP*	-	-	-	-	*	-
en_2590.txt	0	17	not	RB	*	-	-	-	-	*	-
en_2590.txt	0	18	offer	VB	(VP*	-	-	-	-	*	-
en_2590.txt	0	19	immediate	JJ	(NP*	-	-	-	-	*	-
en_2590.txt	0	20	self-sustaining	JJ	*	-	-	-	-	*	-
en_2590.txt	0	21	economic	JJ	*	-	-	-	-	*	-
en_2590.txt	0	22	returns	NNS	*))))))))))	-	-	-	-	*	-
en_2590.txt	0	23	.	.	*))	-	-	-	-	*	-

en_2590.txt	0	0	And	CC	(TOP(S*	-	-	-	-	*	-
en_2590.txt	0	1	funding	NN	(NP(NP*)	-	-	-	-	*	-
en_2590.txt	0	2	for	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	3	basic	JJ	(NP*	-	-	-	-	*	(15
en_2590.txt	0	4	research	NN	*)))	-	-	-	-	*	15)
en_2590.txt	0	5	remains	VBZ	(VP*	-	-	-	-	*	-
en_2590.txt	0	6	a	DT	(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	7	low	JJ	*	-	-	-	-	*	-
en_2590.txt	0	8	priority	NN	*)	-	-	-	-	*	-
en_2590.txt	0	9	in	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	10	emerging	VBG	(NP*	-	-	-	-	*	-
en_2590.txt	0	11	economies	NNS	*))	-	-	-	-	*	-
en_2590.txt	0	12	like	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	13	China	NNP	(NP(NP*)	-	-	-	-	*	-
en_2590.txt	0	14	,	,	*	-	-	-	-	*	-
en_2590.txt	0	15	where	WRB	(SBAR(WHADVP*)	-	-	-	-	*	-
en_2590.txt	0	16	it	PRP	(S(NP*)	-	-	-	-	*	(15)
en_2590.txt	0	17	accounts	VBZ	(VP*	-	-	-	-	*	-
en_2590.txt	0	18	for	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	19	less	JJR	(NP(NP(NP(QP*	-	-	-	-	*	-
en_2590.txt	0	20	than	IN	*	-	-	-	-	*	-
en_2590.txt	0	21	15	CD	*)	-	-	-	-	*	-
en_2590.txt	0	22	cents	NNS	*)	-	-	-	-	*	-
en_2590.txt	0	23	for	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	24	every	DT	(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	25	research	NN	*	-	-	-	-	*	-
en_2590.txt	0	26	dollar	NN	*)	-	-	-	-	*	-
en_2590.txt	0	27	spent	VBN	(VP*))))	-	-	-	-	*	-
en_2590.txt	0	28	-LRB-	-LRB-	(PRN*	-	-	-	-	*	-
en_2590.txt	0	29	compared	VBN	(PP*	-	-	-	-	*	-
en_2590.txt	0	30	to	TO	(PP*	-	-	-	-	*	-
en_2590.txt	0	31	35	CD	(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	32	cents	NNS	*)	-	-	-	-	*	-
en_2590.txt	0	33	in	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	34	the	DT	(NP*	-	-	-	-	*	(5
en_2590.txt	0	35	US	NNP	*)))))	-	-	-	-	*	5)
en_2590.txt	0	36	-RRB-	-RRB-	*))))))))))	-	-	-	-	*	-
en_2590.txt	0	37	.	.	*))	-	-	-	-	*	-

en_2590.txt	0	0	With	IN	(TOP(S(PP*	-	-	-	-	*	-
en_2590.txt	0	1	no	DT	(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	2	panacea	NN	*)	-	-	-	-	*	-
en_2590.txt	0	3	in	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	4	sight	NN	(NP*))))	-	-	-	-	*	-
en_2590.txt	0	5	,	,	*	-	-	-	-	*	-
en_2590.txt	0	6	several	JJ	(NP*	-	-	-	-	*	-
en_2590.txt	0	7	other	JJ	*	-	-	-	-	*	-
en_2590.txt	0	8	solutions	NNS	*)	-	-	-	-	*	-
en_2590.txt	0	9	are	VBP	(VP*	-	-	-	-	*	-
en_2590.txt	0	10	gaining	VBG	(VP*	-	-	-	-	*	-
en_2590.txt	0	11	traction	NN	(NP*)))	-	-	-	-	*	-
en_2590.txt	0	12	.	.	*))	-	-	-	-	*	-

en_2590.txt	0	0	To	TO	(TOP(S(S(VP*	-	-	-	-	*	-
en_2590.txt	0	1	maximize	VB	(VP*	-	-	-	-	*	-
en_2590.txt	0	2	investment	NN	(NP*))))	-	-	-	-	*	-
en_2590.txt	0	3	,	,	*	-	-	-	-	*	-
en_2590.txt	0	4	the	DT	(NP*	-	-	-	-	*	-
en_2590.txt	0	5	public	JJ	(ADJP*	-	-	-	-	*	-
en_2590.txt	0	6	and	CC	*	-	-	-	-	*	-
en_2590.txt	0	7	private	JJ	*)	-	-	-	-	*	-
en_2590.txt	0	8	sectors	NNS	*)	-	-	-	-	*	-
en_2590.txt	0	9	are	VBP	(VP*	-	-	-	-	*	-
en_2590.txt	0	10	increasingly	RB	(ADVP*)	-	-	-	-	*	-
en_2590.txt	0	11	pooling	VBG	(VP*	-	-	-	-	*	-
en_2590.txt	0	12	resources	NNS	(NP*)))	-	-	-	-	*	(16)
en_2590.txt	0	13	.	.	*))	-	-	-	-	*	-

en_2590.txt	0	0	For	IN	(TOP(S(PP*	-	-	-	-	*	-
en_2590.txt	0	1	example	NN	(NP*))	-	-	-	-	*	-
en_2590.txt	0	2	,	,	*	-	-	-	-	*	-
en_2590.txt	0	3	under	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	4	the	DT	(NP*	-	-	-	-	*	-
en_2590.txt	0	5	Accelerating	NNP	*	-	-	-	-	*	-
en_2590.txt	0	6	Medicines	NNP	*	-	-	-	-	*	-
en_2590.txt	0	7	Partnership	NNP	*))	-	-	-	-	*	-
en_2590.txt	0	8	,	,	*	-	-	-	-	*	-
en_2590.txt	0	9	the	DT	(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	10	NIH	NNP	*)	-	-	-	-	*	-
en_2590.txt	0	11	and	CC	*	-	-	-	-	*	-
en_2590.txt	0	12	ten	JJ	(NP*	-	-	-	-	*	-
en_2590.txt	0	13	biopharmaceutical	JJ	*	-	-	-	-	*	-
en_2590.txt	0	14	companies	NNS	*))	-	-	-	-	*	-
en_2590.txt	0	15	will	MD	(VP*	-	-	-	-	*	-
en_2590.txt	0	16	fund	VB	(VP*	-	-	-	-	*	-
en_2590.txt	0	17	a	DT	(NP*	-	-	-	-	*	-
en_2590.txt	0	18	five-year	JJ	*	-	-	-	-	*	-
en_2590.txt	0	19	effort	NN	*	-	-	-	-	*	-
en_2590.txt	0	20	to	TO	(S(VP*	-	-	-	-	*	-
en_2590.txt	0	21	validate	VB	(VP*	-	-	-	-	*	-
en_2590.txt	0	22	promising	JJ	(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	23	targets	NNS	*)	-	-	-	-	*	-
en_2590.txt	0	24	in	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	25	three	CD	(NP*	-	-	-	-	*	-
en_2590.txt	0	26	disease	NN	*	-	-	-	-	*	-
en_2590.txt	0	27	areas	NNS	*)))))))))	-	-	-	-	*	-
en_2590.txt	0	28	.	.	*))	-	-	-	-	*	-

en_2590.txt	0	0	Other	JJ	(TOP(S(NP*	-	-	-	-	*	-
en_2590.txt	0	1	initiatives	NNS	*)	-	-	-	-	*	-
en_2590.txt	0	2	include	VBP	(VP*	-	-	-	-	*	-
en_2590.txt	0	3	efforts	NNS	(NP(NP*)	-	-	-	-	*	(17
en_2590.txt	0	4	in	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	5	Alzheimer	NNP	(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	6	'	POS	*)	-	-	-	-	*	-
en_2590.txt	0	7	s	JJ	*	-	-	-	-	*	-
en_2590.txt	0	8	research	NN	*))	-	-	-	-	*	-
en_2590.txt	0	9	to	TO	(SBAR(S(VP*	-	-	-	-	*	-
en_2590.txt	0	10	test	VB	(VP*	-	-	-	-	*	-
en_2590.txt	0	11	competing	VBG	(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	12	drugs	NNS	*)	-	-	-	-	*	-
en_2590.txt	0	13	against	IN	(PP(PP*	-	-	-	-	*	-
en_2590.txt	0	14	one	CD	(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	15	shared	JJ	*	-	-	-	-	*	-
en_2590.txt	0	16	``	``	*	-	-	-	-	*	-
en_2590.txt	0	17	placebo	NN	*	-	-	-	-	*	-
en_2590.txt	0	18	arm	NN	*	-	-	-	-	*	-
en_2590.txt	0	19	''	''	*)	-	-	-	-	*	-
en_2590.txt	0	20	in	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	21	clinical	JJ	(NP*	-	-	-	-	*	-
en_2590.txt	0	22	trials	NNS	*))))	-	-	-	-	*	-
en_2590.txt	0	23	,	,	*	-	-	-	-	*	-
en_2590.txt	0	24	and	CC	*	-	-	-	-	*	-
en_2590.txt	0	25	in	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	26	cancer	NN	(NP*	-	-	-	-	*	-
en_2590.txt	0	27	research	NN	*))))	-	-	-	-	*	-
en_2590.txt	0	28	to	TO	(S(VP*	-	-	-	-	*	-
en_2590.txt	0	29	test	VB	(VP(VP*	-	-	-	-	*	-
en_2590.txt	0	30	multiple	JJ	(NP*	-	-	-	-	*	-
en_2590.txt	0	31	therapies	NNS	*)	-	-	-	-	*	-
en_2590.txt	0	32	in	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	33	a	DT	(NP*	-	-	-	-	*	-
en_2590.txt	0	34	single	JJ	*	-	-	-	-	*	-
en_2590.txt	0	35	trial	NN	*)))	-	-	-	-	*	-
en_2590.txt	0	36	and	CC	*	-	-	-	-	*	-
en_2590.txt	0	37	identify	VB	(VP*	-	-	-	-	*	-
en_2590.txt	0	38	the	DT	(NP*	-	-	-	-	*	-
en_2590.txt	0	39	most	RBS	(ADJP*	-	-	-	-	*	-
en_2590.txt	0	40	responsive	JJ	*)	-	-	-	-	*	-
en_2590.txt	0	41	patients	NNS	*)))))))))))	-	-	-	-	*	17)
en_2590.txt	0	42	.	.	*))	-	-	-	-	*	-

en_2590.txt	0	0	These	DT	(TOP(S(S(NP*	-	-	-	-	*	(16
en_2590.txt	0	1	pooled	VBN	*	-	-	-	-	*	-
en_2590.txt	0	2	resources	NNS	*)	-	-	-	-	*	16)
en_2590.txt	0	3	will	MD	(VP*	-	-	-	-	*	-
en_2590.txt	0	4	be	VB	(VP*	-	-	-	-	*	-
en_2590.txt	0	5	directed	VBN	(VP*	-	-	-	-	*	-
en_2590.txt	0	6	to	TO	(PP*	-	-	-	-	*	-
en_2590.txt	0	7	a	DT	(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	8	few	JJ	*	-	-	-	-	*	-
en_2590.txt	0	9	high-priority	JJ	*	-	-	-	-	*	-
en_2590.txt	0	10	diseases	NNS	*)	-	-	-	-	*	-
en_2590.txt	0	11	,	,	*	-	-	-	-	*	-
en_2590.txt	0	12	identified	VBN	(VP*	-	-	-	-	*	-
en_2590.txt	0	13	through	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	14	an	DT	(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	15	evaluation	NN	*)	-	-	-	-	*	-
en_2590.txt	0	16	of	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	17	the	DT	(NP(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	18	marginal	JJ	*	-	-	-	-	*	-
en_2590.txt	0	19	benefit	NN	*)	-	-	-	-	*	-
en_2590.txt	0	20	of	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	21	additional	JJ	(NP*	-	-	-	-	*	-
en_2590.txt	0	22	R	NN	*)))	-	-	-	-	*	-
en_2590.txt	0	23	&	CC	*	-	-	-	-	*	-
en_2590.txt	0	24	D.	NNP	(NP(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	25	Japan	NNP	*	-	-	-	-	*	-
en_2590.txt	0	26	'	POS	*)	-	-	-	-	*	-
en_2590.txt	0	27	s	RB	(ADJP*	-	-	-	-	*	-
en_2590.txt	0	28	focused	VBN	*)	-	-	-	-	*	-
en_2590.txt	0	29	strategy	NN	*)	-	-	-	-	*	-
en_2590.txt	0	30	to	TO	(PP*	-	-	-	-	*	-
en_2590.txt	0	31	champion	JJ	(NP*	-	-	-	-	*	-
en_2590.txt	0	32	stem-cell	JJ	*	-	-	-	-	*	-
en_2590.txt	0	33	R	NN	*))))))))))))))	-	-	-	-	*	-
en_2590.txt	0	34	&	CC	*	-	-	-	-	*	-
en_2590.txt	0	35	D	NNP	(S(NP*)	-	-	-	-	*	(5)
en_2590.txt	0	36	should	MD	(VP*	-	-	-	-	*	-
en_2590.txt	0	37	serve	VB	(VP*	-	-	-	-	*	-
en_2590.txt	0	38	as	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	39	a	DT	(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	40	model	NN	*)	-	-	-	-	*	-
en_2590.txt	0	41	for	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	42	other	JJ	(NP*	-	-	-	-	*	-
en_2590.txt	0	43	countries	NNS	*)))))))	-	-	-	-	*	-
en_2590.txt	0	44	.	.	*))	-	-	-	-	*	-

en_2590.txt	0	0	At	IN	(TOP(S(PP*	-	-	-	-	*	-
en_2590.txt	0	1	the	DT	(NP*	-	-	-	-	*	-
en_2590.txt	0	2	same	JJ	*	-	-	-	-	*	-
en_2590.txt	0	3	time	NN	*))	-	-	-	-	*	-
en_2590.txt	0	4	,	,	*	-	-	-	-	*	-
en_2590.txt	0	5	governments	NNS	(NP*)	-	-	-	-	*	-
en_2590.txt	0	6	will	MD	(VP*	-	-	-	-	*	-
en_2590.txt	0	7	have	VB	(VP*	-	-	-	-	*	-
en_2590.txt	0	8	to	TO	(S(VP*	-	-	-	-	*	-
en_2590.txt	0	9	implement	VB	(VP*	-	-	-	-	*	-
en_2590.txt	0	10	policies	NNS	(NP(NP*)	-	-	-	-	*	-
en_2590.txt	0	11	aimed	VBN	(VP*	-	-	-	-	*	-
en_2590.txt	0	12	at	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	13	guiding	VBG	(S(VP*	-	-	-	-	*	-
en_2590.txt	0	14	investment	NN	(NP(NP*)	-	-	-	-	*	-
en_2590.txt	0	15	toward	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	16	specific	JJ	(NP*	-	-	-	-	*	-
en_2590.txt	0	17	diseases	NNS	*)))))))))))))	-	-	-	-	*	-
en_2590.txt	0	18	.	.	*))	-	-	-	-	*	-

en_2590.txt	0	0	For	IN	(TOP(S(PP*	-	-	-	-	*	-
en_2590.txt	0	1	example	NN	(NP*))	-	-	-	-	*	-
en_2590.txt	0	2	,	,	*	-	-	-	-	*	-
en_2590.txt	0	3	increased	VBN	(NP(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	4	NIH	NNP	*	-	-	-	-	*	-
en_2590.txt	0	5	funding	NN	*)	-	-	-	-	*	-
en_2590.txt	0	6	,	,	*	-	-	-	-	*	-
en_2590.txt	0	7	extended	VBN	(NP*	-	-	-	-	*	-
en_2590.txt	0	8	market	NN	*	-	-	-	-	*	-
en_2590.txt	0	9	exclusivity	NN	*)	-	-	-	-	*	-
en_2590.txt	0	10	,	,	*	-	-	-	-	*	-
en_2590.txt	0	11	and	CC	*	-	-	-	-	*	-
en_2590.txt	0	12	relaxed	VBN	(NP*	-	-	-	-	*	-
en_2590.txt	0	13	regulatory	JJ	*	-	-	-	-	*	-
en_2590.txt	0	14	hurdles	NNS	*))	-	-	-	-	*	-
en_2590.txt	0	15	in	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	16	the	DT	(NP*	-	-	-	-	*	(5
en_2590.txt	0	17	US	NNP	*)))	-	-	-	-	*	5)
en_2590.txt	0	18	resulted	VBD	(VP*	-	-	-	-	*	-
en_2590.txt	0	19	in	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	20	a	DT	(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	21	renaissance	NN	*)	-	-	-	-	*	-
en_2590.txt	0	22	in	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	23	antibiotic	JJ	(NP*	-	-	-	-	*	-
en_2590.txt	0	24	drug	NN	*	-	-	-	-	*	-
en_2590.txt	0	25	development	NN	*)))))	-	-	-	-	*	-
en_2590.txt	0	26	.	.	*))	-	-	-	-	*	-

en_2590.txt	0	0	Society	NNP	(TOP(S(NP*)	-	-	-	-	*	-
en_2590.txt	0	1	will	MD	(VP*	-	-	-	-	*	-
en_2590.txt	0	2	also	RB	(ADVP*)	-	-	-	-	*	-
en_2590.txt	0	3	have	VB	(VP*	-	-	-	-	*	-
en_2590.txt	0	4	to	TO	(S(VP*	-	-	-	-	*	-
en_2590.txt	0	5	share	VB	(VP*	-	-	-	-	*	-
en_2590.txt	0	6	the	DT	(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	7	cost	NN	*)	-	-	-	-	*	-
en_2590.txt	0	8	of	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	9	drug	NN	(NP*	-	-	-	-	*	-
en_2590.txt	0	10	development	NN	*))))))))	-	-	-	-	*	-
en_2590.txt	0	11	.	.	*))	-	-	-	-	*	-

en_2590.txt	0	0	Regulatory	NNP	(TOP(S(NP*	-	-	-	-	*	-
en_2590.txt	0	1	agencies	NNS	*)	-	-	-	-	*	-
en_2590.txt	0	2	worldwide	RB	(ADVP*)	-	-	-	-	*	-
en_2590.txt	0	3	may	MD	(VP*	-	-	-	-	*	-
en_2590.txt	0	4	follow	VB	(VP*	-	-	-	-	*	-
en_2590.txt	0	5	the	DT	(NP(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	6	United	NNP	*	-	-	-	-	*	-
en_2590.txt	0	7	Kingdom	NNP	*	-	-	-	-	*	-
en_2590.txt	0	8	'	POS	*)	-	-	-	-	*	-
en_2590.txt	0	9	s	JJ	*	-	-	-	-	*	-
en_2590.txt	0	10	lead	NN	*)	-	-	-	-	*	-
en_2590.txt	0	11	in	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	12	embracing	VBG	(S(VP*	-	-	-	-	*	-
en_2590.txt	0	13	adaptive	JJ	(NP*	-	-	-	-	*	-
en_2590.txt	0	14	licensing	NN	*)))))))	-	-	-	-	*	-
en_2590.txt	0	15	.	.	*))	-	-	-	-	*	-

en_2590.txt	0	0	Under	IN	(TOP(S(PP*	-	-	-	-	*	-
en_2590.txt	0	1	this	DT	(NP*	-	-	-	-	*	-
en_2590.txt	0	2	approach	NN	*))	-	-	-	-	*	-
en_2590.txt	0	3	,	,	*	-	-	-	-	*	-
en_2590.txt	0	4	drugs	NNS	(NP*)	-	-	-	-	*	-
en_2590.txt	0	5	are	VBP	(VP*	-	-	-	-	*	-
en_2590.txt	0	6	conditionally	RB	(VP(VP(ADVP*)	-	-	-	-	*	-
en_2590.txt	0	7	approved	VBN	*)	-	-	-	-	*	-
en_2590.txt	0	8	and	CC	*	-	-	-	-	*	-
en_2590.txt	0	9	marketed	VBN	*	-	-	-	-	*	-
en_2590.txt	0	10	,	,	*	-	-	-	-	*	-
en_2590.txt	0	11	with	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	12	the	DT	(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	13	revenue	NN	*)	-	-	-	-	*	-
en_2590.txt	0	14	generated	VBN	(VP*	-	-	-	-	*	-
en_2590.txt	0	15	following	VBG	(PP*	-	-	-	-	*	-
en_2590.txt	0	16	the	DT	(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	17	conditional	JJ	*	-	-	-	-	*	-
en_2590.txt	0	18	approval	NN	*)	-	-	-	-	*	-
en_2590.txt	0	19	covering	VBG	(VP*	-	-	-	-	*	-
en_2590.txt	0	20	the	DT	(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	21	costly	JJ	*	-	-	-	-	*	-
en_2590.txt	0	22	trial	NN	*)	-	-	-	-	*	-
en_2590.txt	0	23	for	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	24	proving	VBG	(NP*	-	-	-	-	*	-
en_2590.txt	0	25	efficacy	NN	*)))))))))))	-	-	-	-	*	-
en_2590.txt	0	26	.	.	*))	-	-	-	-	*	-

en_2590.txt	0	0	Such	PDT	(TOP(S(NP*	-	-	-	-	*	-
en_2590.txt	0	1	a	DT	*	-	-	-	-	*	-
en_2590.txt	0	2	scheme	NN	*)	-	-	-	-	*	-
en_2590.txt	0	3	facilitates	VBZ	(VP*	-	-	-	-	*	-
en_2590.txt	0	4	lower	JJR	(NP*	-	-	-	-	*	-
en_2590.txt	0	5	drug	NN	*	-	-	-	-	*	-
en_2590.txt	0	6	pricing	NN	*)	-	-	-	-	*	-
en_2590.txt	0	7	,	,	*	-	-	-	-	*	-
en_2590.txt	0	8	while	IN	(SBAR*	-	-	-	-	*	-
en_2590.txt	0	9	overcoming	VBG	(S(VP*	-	-	-	-	*	-
en_2590.txt	0	10	the	DT	(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	11	effect	NN	*)	-	-	-	-	*	-
en_2590.txt	0	12	of	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	13	Eroom	NNP	(NP(NP*	-	-	-	-	*	(2
en_2590.txt	0	14	'	POS	*)	-	-	-	-	*	2)
en_2590.txt	0	15	s	JJ	*	-	-	-	-	*	-
en_2590.txt	0	16	law	NN	*)))	-	-	-	-	*	-
en_2590.txt	0	17	on	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	18	investment	NN	(NP(NP*)	-	-	-	-	*	-
en_2590.txt	0	19	in	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	20	treatments	NNS	(NP(NP*)	-	-	-	-	*	-
en_2590.txt	0	21	for	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	22	many	JJ	(NP*	-	-	-	-	*	-
en_2590.txt	0	23	diseases	NNS	*))))))))))	-	-	-	-	*	-
en_2590.txt	0	24	.	.	*))	-	-	-	-	*	-

en_2590.txt	0	0	Whether	IN	(TOP(SINV(PP*	-	-	-	-	*	-
en_2590.txt	0	1	these	DT	(S(NP*	-	-	-	-	*	(17
en_2590.txt	0	2	efforts	NNS	*)	-	-	-	-	*	17)
en_2590.txt	0	3	will	MD	(VP*	-	-	-	-	*	-
en_2590.txt	0	4	succeed	VB	(VP*	-	-	-	-	*	-
en_2590.txt	0	5	in	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	6	putting	VBG	(S(VP*	-	-	-	-	*	-
en_2590.txt	0	7	biomedical	JJ	(NP*	-	-	-	-	*	-
en_2590.txt	0	8	research	NN	*)	-	-	-	-	*	-
en_2590.txt	0	9	on	IN	(PP*	-	-	-	-	*	-
en_2590.txt	0	10	a	DT	(NP*	-	-	-	-	*	-
en_2590.txt	0	11	more	RBR	(ADJP*	-	-	-	-	*	-
en_2590.txt	0	12	sustainable	JJ	*)	-	-	-	-	*	-
en_2590.txt	0	13	footing	NN	*)))))))))	-	-	-	-	*	-
en_2590.txt	0	14	remains	VBZ	(VP*)	-	-	-	-	*	-
en_2590.txt	0	15	an	DT	(NP*	-	-	-	-	*	-
en_2590.txt	0	16	open	JJ	*	-	-	-	-	*	-
en_2590.txt	0	17	question	NN	*)	-	-	-	-	*	-
en_2590.txt	0	18	.	.	*))	-	-	-	-	*	-

en_2590.txt	0	0	This	DT	(TOP(S(NP*)	-	-	-	-	*	-
en_2590.txt	0	1	could	MD	(VP*	-	-	-	-	*	-
en_2590.txt	0	2	still	RB	(ADVP*)	-	-	-	-	*	-
en_2590.txt	0	3	turn	VB	(VP*	-	-	-	-	*	-
en_2590.txt	0	4	out	RP	(PRT*)	-	-	-	-	*	-
en_2590.txt	0	5	to	TO	(S(VP*	-	-	-	-	*	-
en_2590.txt	0	6	be	VB	(VP*	-	-	-	-	*	-
en_2590.txt	0	7	biology	NNS	(NP(NP*	-	-	-	-	*	-
en_2590.txt	0	8	'	POS	*)	-	-	-	-	*	-
en_2590.txt	0	9	s	JJ	*	-	-	-	-	*	-
en_2590.txt	0	10	century	NN	*))))))	-	-	-	-	*	-
en_2590.txt	0	11	.	.	*))	-	-	-	-	*	-

#end document
